Silica Corpora was born as a result of the main purpose of the founders, Timofei and Jaime, to respond to challenges in drug discovery exploiting recent advances in computational technologies.
Design, not discovery
The estimated cost of bringing a new prescription drug to the market has risen dramatically from $1.1B in 2003 to $2.3B in 2019 while early stages of drug discovery take around 3 years. The replacement of lead generation and lead optimization stages of antibody drug discovery with AI may reduce the times and costs of early antibody discovery by 10-100 times while improving its quality and accuracy.
"Our mission is to develop tailored AI-solutions to develop more-quality and more cost-effective antibody therapeutics, turning historical data of previous Drug Discovery projects into valuable assets, significantly reducing the prospective sunk costs."
Our expertise supports our results
Head of Business Development
Jaime has a Bachelor’s in Mechanical Engineering and a Master of Science in Advanced Physics and Applied Mathematics, and an MBA in Life Science Management. He has more than 5 years of experience in Project Management, Performance Management and Social Media Management. His multidisciplinary background has helped him to build strong analytical skills, expert communication, and people skills.
Head of AI & Bioinformatics
Tim has more than 7 years of experience in the development of computational methods for antibody optimization in the role of AI/ML Team Lead for Structural Bioinformatics in an R&D department of a fully integrated biotech company, and more than 10 years of experience in bioinformatics. He holds a bachelor’s and a Master of Science degrees in Computer Science, and an MBA&E in Life Science Management.
Our Journey So Far
SILICA CORPORA IS FOUNDED
Jaime and Tim started the company when they received financing from REACT Scholarship, a Startup Incubator Berlin (SIB) program for health tech Start-ups.
FIRST MVP COMPLETION
In this stage, our platform can generate CDRs from scratch, given a target sequence and epitope. Moreover, the platform is capable of binding affinity optimization given sequences of a target and antibody candidates.